Dementia risk in patients with type 2 diabetes : Comparing metformin with no pharmacological treatment
© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association..
INTRODUCTION: Metformin has been suggested as a therapeutic agent for dementia, but the relevant evidence has been partial and inconsistent.
METHODS: We established a national cohort of 210,237 type 2 diabetes patients in the UK Clinical Practice Research Datalink. Risks of incident dementia were compared between metformin initiators and those who were not prescribed any anti-diabetes medication during follow-up.
RESULTS: Compared with metformin initiators (n = 114,628), patients who received no anti-diabetes medication (n = 95,609) had lower HbA1c and better cardiovascular health at baseline. Both Cox regression and propensity score weighting analysis showed metformin initiators had lower risk of dementia compared to those non-users (adjusted hazard ratio = 0.88 [95% confidence interval: 0.84-0.92] and 0.90 [0.84-0.96]). Patients on long-term metformin treatment had an even lower risk of dementia.
DISCUSSION: Metformin may act beyond its glycemic effect and reduce dementia risk to an even lower level than that of patients with milder diabetes and better health profiles.
HIGHLIGHTS: Metformin initiators had a significantly lower risk of dementia compared with patients not receiving anti-diabetes medication. Compared with metformin initiators, diabetes patients not receiving pharmacological treatment had better glycemic profiles at baseline and during follow-up. Patients on long-term metformin treatment had an even lower risk of subsequent dementia incidence. Metformin may act beyond its effect on hyperglycemia and has the potential of being repurposed for dementia prevention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Alzheimer's & dementia : the journal of the Alzheimer's Association - 19(2023), 12 vom: 11. Dez., Seite 5681-5689 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Bang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9100L32L2N |
|---|
| Anmerkungen: |
Date Completed 29.12.2023 Date Revised 29.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/alz.13349 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358963796 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358963796 | ||
| 003 | DE-627 | ||
| 005 | 20240108135904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alz.13349 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1242.xml |
| 035 | |a (DE-627)NLM358963796 | ||
| 035 | |a (NLM)37395154 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Bang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dementia risk in patients with type 2 diabetes |b Comparing metformin with no pharmacological treatment |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2023 | ||
| 500 | |a Date Revised 29.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association. | ||
| 520 | |a INTRODUCTION: Metformin has been suggested as a therapeutic agent for dementia, but the relevant evidence has been partial and inconsistent | ||
| 520 | |a METHODS: We established a national cohort of 210,237 type 2 diabetes patients in the UK Clinical Practice Research Datalink. Risks of incident dementia were compared between metformin initiators and those who were not prescribed any anti-diabetes medication during follow-up | ||
| 520 | |a RESULTS: Compared with metformin initiators (n = 114,628), patients who received no anti-diabetes medication (n = 95,609) had lower HbA1c and better cardiovascular health at baseline. Both Cox regression and propensity score weighting analysis showed metformin initiators had lower risk of dementia compared to those non-users (adjusted hazard ratio = 0.88 [95% confidence interval: 0.84-0.92] and 0.90 [0.84-0.96]). Patients on long-term metformin treatment had an even lower risk of dementia | ||
| 520 | |a DISCUSSION: Metformin may act beyond its glycemic effect and reduce dementia risk to an even lower level than that of patients with milder diabetes and better health profiles | ||
| 520 | |a HIGHLIGHTS: Metformin initiators had a significantly lower risk of dementia compared with patients not receiving anti-diabetes medication. Compared with metformin initiators, diabetes patients not receiving pharmacological treatment had better glycemic profiles at baseline and during follow-up. Patients on long-term metformin treatment had an even lower risk of subsequent dementia incidence. Metformin may act beyond its effect on hyperglycemia and has the potential of being repurposed for dementia prevention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cohort | |
| 650 | 4 | |a dementia | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a type 2 diabetes | |
| 650 | 7 | |a Metformin |2 NLM | |
| 650 | 7 | |a 9100L32L2N |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Su, Bowen |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi-Abhari, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Kapogiannis, Dimitrios |e verfasserin |4 aut | |
| 700 | 1 | |a Tzoulaki, Ioanna |e verfasserin |4 aut | |
| 700 | 1 | |a Riboli, Elio |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Lefkos |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alzheimer's & dementia : the journal of the Alzheimer's Association |d 2005 |g 19(2023), 12 vom: 11. Dez., Seite 5681-5689 |w (DE-627)NLM168942356 |x 1552-5279 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:12 |g day:11 |g month:12 |g pages:5681-5689 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alz.13349 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 12 |b 11 |c 12 |h 5681-5689 | ||